Furthermore, Accardo et al. (2019) conducted a preliminary animal study in 2019 on prostate cancer xenograft mouse models and confirmed that bombesin-modified liposomal doxorubicin could effectively reduce tumor growth in comparison to plain liposomal doxorubicin. Here, GRP is linked to neoplasm.